PpProf. Peptide
← Back to Supplement Library

Curcumin

Recovery & Tissue Repair

Last reviewed: May 26, 2026

Also Known As: Turmeric extract, diferuloylmethane, curcuminoids, BCM-95, Meriva (phytosome), Theracurmin (nanoparticle), Longvida (lipid-coated)

Supplement Class: Polyphenol (turmeric-derived) / NF-κB inhibitor / COX-LOX inhibitor / anti-inflammatory adjunct

Evidence Tier: Strong — Paultre 2021 meta-analysis of 16 RCTs (n=1,810) for knee osteoarthritis with NSAID-comparable effect sizes; Hanai 2006 for ulcerative colitis remission maintenance; Fernández-Lázaro 2020 for exercise recovery; Hewlings 2017 review covering the broader evidence landscape. Effect is strongly formulation-dependent (bioavailability gates outcomes).

What is curcumin?

Curcumin is the primary bioactive polyphenol in turmeric (Curcuma longa) — the bright yellow spice used for thousands of years in Ayurvedic and traditional Chinese medicine, and now one of the most extensively studied natural compounds in modern supplement research (over 3,000 published studies). Its core mechanism is inhibition of NF-κB — the master transcription factor that activates inflammatory gene expression — with secondary inhibition of COX/LOX enzymes (the same pathways NSAIDs target). The result is broad anti-inflammatory effects with measurable clinical benefit: NSAID-comparable pain and functional improvement in knee osteoarthritis (Paultre 2021 meta-analysis, n=1,810), maintenance of ulcerative colitis remission (Hanai 2006, ~5× lower relapse vs placebo), reduced exercise-induced muscle damage and soreness, modest antidepressant effects, and emerging evidence in cardiovascular and metabolic contexts. The dominant practical challenge for curcumin is bioavailability — standard curcumin powder has near-zero oral absorption (single-digit nanomolar plasma concentrations), and clinical effect depends on formulation choice. Patented high-bioavailability formulations (Meriva, Theracurmin, BCM-95, Longvida) produce 7–30× higher plasma curcumin; piperine (BioPerine) co-administration produces ~20× via inhibiting hepatic glucuronidation. Curcumin pairs naturally with healing peptides like BPC-157 and TB-500 because the anti-inflammatory mechanism complements direct tissue-repair signaling.

Reported benefits:

  • Knee osteoarthritis pain reduction and functional improvement (Paultre 2021 meta-analysis, NSAID-comparable)
  • Ulcerative colitis remission maintenance (Hanai 2006, ~5× lower relapse vs placebo)
  • Reduced exercise-induced muscle damage and soreness (Fernández-Lázaro 2020)
  • Antidepressant effects comparable to SSRIs in mild-moderate depression (Sanmukhani 2014)
  • Reduced LDL oxidation and improved endothelial function
  • Modest insulin sensitivity improvement
  • Broad NF-κB and COX/LOX inhibition with significantly fewer GI side effects than NSAIDs

Common dose: Formulation-dependent. Meriva 200–500 mg twice daily; Theracurmin 90–180 mg twice daily; BCM-95 500 mg twice daily; standard curcumin + piperine 1,000–2,000 mg + 5–20 mg piperine daily. Always with fat-containing meals. Anti-inflammatory effects emerge over 4–8 weeks of consistent dosing.

Pre-surgical washout: Stop curcumin 1–2 weeks before scheduled surgery — mild antiplatelet effect can increase bleeding risk. Coordinate with anticoagulation clinic if you're on chronic warfarin, apixaban, rivaroxaban, or clopidogrel.

Shop Curcumin on Amazon →

How does curcumin work?

Curcumin works primarily through NF-κB inhibition — blocking the master transcription factor that activates inflammatory gene expression. Secondary mechanisms include COX/LOX inhibition (the same pathways NSAIDs target), BDNF upregulation in the brain, and direct free-radical scavenging. The bioavailability problem (standard curcumin is essentially non-absorbed) is the central practical issue that gates all of these mechanisms in vivo.

  1. NF-κB inhibition — the primary anti-inflammatory mechanism. Curcumin directly inhibits IκB kinase, preventing degradation of IκB and blocking NF-κB nuclear translocation. This reduces transcription of inflammatory cytokines (TNF-α, IL-1β, IL-6), COX-2, iNOS, and other inflammatory mediators. The breadth of NF-κB's gene targets explains curcumin's wide-spectrum anti-inflammatory effects across joints, gut, vasculature, and neural tissue.
  2. COX/LOX enzyme inhibition. Curcumin inhibits cyclooxygenase (COX-1 and COX-2) and lipoxygenase enzymes — the same targets as NSAIDs and aspirin — reducing prostaglandin and leukotriene synthesis. This is the mechanism underlying curcumin's analgesic and anti-inflammatory effects that produce NSAID-comparable benefits in joint pain trials.
  3. BDNF upregulation. Curcumin increases brain-derived neurotrophic factor expression in animal and limited human studies. BDNF supports neuroplasticity, neuronal survival, and is reduced in depression and neurodegenerative disease. This is the mechanistic basis for emerging evidence on curcumin in mood and cognitive applications.
  4. Antioxidant activity. Curcumin directly scavenges free radicals and upregulates endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase). The antioxidant arm contributes to the cardiovascular and neuroprotective effects documented in preclinical and emerging human evidence.
  5. Bioavailability — the central practical constraint. Standard curcumin is hydrophobic, rapidly conjugated by hepatic glucuronidation/sulfation, and excreted — producing single-digit nanomolar plasma concentrations from gram-doses. High-bioavailability formulations (Meriva phospholipid complex, Theracurmin nanoparticles, BCM-95, Longvida, piperine co-administration) produce 7–30× higher plasma curcumin and are essential for clinical effect. Standard turmeric powder or generic curcumin at typical supplemental doses is largely a placebo by oral route.

What does curcumin actually do?

Curcumin has one of the deeper traditional-compound RCT bases in modern dietary supplement research. The strongest evidence is for osteoarthritis pain (NSAID-comparable in multiple head-to-head trials) and ulcerative colitis maintenance. Exercise recovery, cardiovascular biomarkers, and mood applications are emerging. The clinical evidence is contingent on formulation — standard low-bioavailability curcumin underperforms in most trials.

  1. Osteoarthritis pain and function (Strong). Paultre 2021 meta-analysis (16 RCTs, n=1,810) demonstrated significant VAS pain reduction and WOMAC functional improvement with curcumin in knee osteoarthritis — comparable to NSAIDs in head-to-head trials with significantly fewer GI adverse events.
  2. Ulcerative colitis remission maintenance (Moderate-Strong). Hanai 2006 RCT (n=89) demonstrated 1 g curcumin twice daily reduced UC relapse rates versus placebo (4.65% vs 20.51%) over 6 months. Replicated in subsequent trials and supports curcumin as an evidence-based UC maintenance adjunct.
  3. Exercise-induced muscle damage and soreness (Moderate). Fernández-Lázaro 2020 systematic review (11 RCTs) found consistent reductions in CK, IL-6, TNF-α, and muscle soreness with curcumin supplementation around strenuous exercise. Effect sizes are modest; the evidence is similar in magnitude to the tart cherry recovery literature.
  4. Depression as adjunct (Moderate). Several RCTs show curcumin produces antidepressant effects comparable to standard SSRIs in mild-to-moderate depression, with proposed mechanism through BDNF upregulation and anti-inflammatory effects. Effect sizes are modest; not a substitute for established antidepressant treatment in moderate-to-severe depression.
  5. Cardiovascular biomarkers (Moderate). Curcumin supplementation modestly reduces LDL oxidation, improves endothelial function, and reduces inflammatory markers (CRP, IL-6) in dyslipidemic populations. Hard cardiovascular outcomes data is limited.
  6. Type 2 diabetes prevention (Emerging). A 9-month trial in prediabetic adults found curcumin reduced progression to T2D versus placebo, with mechanisms including improved insulin sensitivity. Replication data is thinner.
  7. Cognitive function and Alzheimer's (Emerging). Mechanistic case for BDNF and anti-amyloid effects is strong; clinical trial results in Alzheimer's and MCI populations have been mixed, partly attributable to bioavailability variation across formulations.
  8. Cancer adjunct (Preclinical/Early). Extensive preclinical evidence; some early human trial data in colorectal and prostate cancer. Whether curcumin meaningfully alters cancer outcomes in humans at supplemental doses remains an open clinical question.

How is curcumin dosed?

Curcumin dosing depends entirely on formulation — that's the dominant practical reality. A 200 mg dose of Meriva (curcumin-phospholipid complex) delivers comparable plasma curcumin to 6 g of standard curcumin powder. The supplemental market's dose ranges are bewildering because they don't account for formulation. Always select a clinically-validated formulation first; then follow its trial-validated dose.

  1. Meriva (phytosome complex). 200–500 mg twice daily — the trial-validated range. ~29× absorption vs standard curcumin.
  2. Theracurmin (nanoparticle). 90–180 mg twice daily — trial-validated, ~27× absorption vs standard.
  3. BCM-95 (curcumin + turmeric oils). 500 mg twice daily — ~7× absorption; commonly used in osteoarthritis trials.
  4. Longvida (lipid-coated). 400–800 mg/day — trial-validated, particularly in cognitive applications.
  5. Standard curcumin + piperine. 1,000–2,000 mg curcumin + 5–20 mg piperine (BioPerine) daily — ~20× absorption vs curcumin alone. Cheaper than patented formulations; trial-validated for some endpoints.
  6. Avoid: standard turmeric powder or generic curcumin extract without piperine or bioavailability enhancement. Essentially placebo at typical supplemental doses.

Timeline: anti-inflammatory and joint-pain effects typically emerge over 4–8 weeks. Don't evaluate at 1–2 weeks. Exercise-recovery effects are dose-coupled and operative within 5–10 days of supplementation.

Label math. “Turmeric 1,000 mg with 95% curcuminoids” = 950 mg curcuminoid content but near-zero plasma absorption without piperine or bioavailability formulation. Reading “mg of curcumin” without understanding the absorption profile is misleading. Always read for the patented bioavailability formulation name (Meriva, Theracurmin, BCM-95, Longvida) or piperine co-administration.

How to take curcumin

Curcumin is taken orally as capsules (the dominant form) or occasionally as a powder mixed into golden-milk preparations. Topical use exists for limited cosmetic applications. The practical considerations are formulation choice (the dominant variable), fat coadministration (curcumin is fat-soluble), and timing relative to other medications.

AspectRecommendation
FrequencyTwice daily preferred (curcumin half-life is short, ~2 hours; split dosing maintains steady-state plasma levels). Once daily is acceptable for general use.
Best time of dayWith meals — particularly fat-containing meals for absorption. Split AM + PM for steady-state effect. For osteoarthritis pain: timing with meals; effect is cumulative not acute.
FoodALWAYS with fat-containing meals — curcumin is fat-soluble and absorption is meaningfully fat-dependent (less critical for patented bioavailability formulations, still helpful).
FormPatented bioavailability formulations (Meriva, Theracurmin, BCM-95, Longvida) for trial-validated absorption; standard curcumin + piperine (BioPerine) as cheaper alternative; avoid plain turmeric powder or generic curcumin without piperine.
Standardization markerLook for patented formulation name (Meriva, Theracurmin, BCM-95, Longvida) OR “95% curcuminoids + piperine/BioPerine” for the budget option. Avoid “turmeric extract” with no bioavailability marker — essentially placebo.
CyclingNo cycling needed for general use — chronic daily use is the trial-validated model. For exercise recovery: pulse around hard training events (5–10 days surrounding).

What does curcumin stack with?

Curcumin pairs naturally with the broader anti-inflammatory and tissue-recovery toolkit. The NF-κB inhibition + COX/LOX inhibition mechanism complements peptides operating on direct tissue-repair signaling, omega-3 anti-inflammatory effects, and joint-support nutritional adjuncts. The three areas below cover the natural stacking categories.

With peptides

Curcumin pairs naturally with the healing peptide cluster. BPC-157 is a healing peptide that accelerates tissue repair through angiogenic and growth-factor signaling — particularly relevant for tendon, ligament, and gut injuries. TB-500 (thymosin beta-4 fragment) supports cell migration, wound healing, and tissue regeneration. KPV (anti-inflammatory tripeptide, C-terminal of α-MSH) reduces tissue inflammation via melanocortin pathway. Curcumin operates at a different layer: NF-κB inhibition and COX/LOX reduction blunt the systemic inflammatory background that's often the limiting factor in injury healing. The peptides drive repair signaling; curcumin reduces the inflammatory tide. Mechanistically complementary, no known negative interactions. The healing-cluster pairing (peptides + curcumin + collagen + omega-3) is one of the more mechanistically natural multi-modal recovery protocols.

With supplements

  1. Omega-3 fish oil — EPA/DHA modulate different inflammatory pathways (resolvins, protectins) than curcumin. Complementary anti-inflammatory arms; one of the more evidence-supported pairings in inflammation-modulation protocols.
  2. Collagen peptides — structural support for joints and connective tissue. Complements curcumin's anti-inflammatory arm for joint health.
  3. Quercetin — additional anti-inflammatory flavonoid with senolytic effects. Compatible co-occupant in anti-inflammation stacks.
  4. Zinc carnosine — gut-lining support. Pairs with curcumin for IBD or gut-inflammation contexts.
  5. Tart cherry — anthocyanin anti-inflammatory and exercise-recovery effects. Compatible with curcumin in training-block recovery protocols.

With lifestyle

  1. Take with fat-containing meals. Curcumin absorption is meaningfully fat-dependent; meal coadministration improves bioavailability for all formulations.
  2. Anti-inflammatory dietary background. Mediterranean diet, lower omega-6 intake, reduced ultra-processed food intake all reduce baseline inflammation. Curcumin works on top of dietary foundation, not as a substitute.
  3. Pre-surgical washout. Stop curcumin 1–2 weeks before scheduled surgery (mild antiplatelet effect). Add to your pre-op checklist.
  4. Hard training blocks. Pulse 5–10 days surrounding peak training events for exercise-recovery benefits (Fernández-Lázaro 2020 protocol).
  5. NSAID rotation. For chronic mild-to-moderate joint pain, alternating periods of curcumin and NSAIDs may reduce GI side effects of chronic NSAID use while maintaining pain control.

Side effects and interactions

Curcumin has an excellent safety profile in clinical trials. The main practical considerations are mild GI effects, the antiplatelet interaction with anticoagulants (clinically relevant for surgery and chronic anticoagulation users), and iron-absorption interference.

Common (mostly transient)

  1. Mild GI discomfort — occasional nausea, diarrhea, or stomach upset at higher doses (1 g+). Resolves with food coadministration or dose reduction.
  2. Yellow-orange staining of urine or stool — harmless cosmetic effect from curcumin pigment excretion.
  3. No documented serious adverse events at supplemental doses across the human trial base.

Less common (watch-list)

  1. Antiplatelet effect (clinically relevant). Mild but documented; matters for users on anticoagulants and for pre-surgical considerations. Stop curcumin 1–2 weeks before scheduled surgery.
  2. Iron absorption interference — curcumin chelates iron in the gut and may reduce iron absorption. Relevant for iron-deficient or iron-supplementing users; separate iron supplement dosing by 2+ hours.
  3. Gallbladder issues — curcumin stimulates gallbladder contraction; may exacerbate symptoms in users with gallstones or biliary obstruction.

Drug and supplement interactions

  1. Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel). Additive antiplatelet/anticoagulant effect. Coordinate with prescribing clinician; INR monitoring for warfarin users.
  2. NSAIDs and aspirin. Additive antiplatelet effect; modest additional bleeding risk. Generally tolerated but worth flagging for chronic high-dose NSAID users.
  3. Iron supplements — separate dosing by 2+ hours to avoid chelation-mediated absorption interference.
  4. Chemotherapy — curcumin has both pro- and anti-cancer effects depending on context; some chemotherapy regimens may be affected. Coordinate with oncologist.
  5. Diabetes medications — curcumin modestly improves insulin sensitivity; additive glucose-lowering with insulin, sulfonylureas, GLP peptides. Monitor glucose during titration.
  6. Pregnancy and breastfeeding — high supplemental doses not recommended; culinary use is fine. Insufficient data for therapeutic dosing safety.

What we don't know yet about curcumin

Curcumin has one of the deeper supplement evidence bases for inflammation and pain, but several open questions affect how confidently it can be recommended for specific use cases — particularly around formulation-dependent outcome variability, healthy-adult primary-prevention transfer, and the cancer-context dual role.

Formulation-dependent clinical effects. Most negative or null curcumin trials used standard low-bioavailability curcumin where plasma concentrations didn't reach effective ranges. The Paultre 2021 meta-analysis used trials with mixed formulations; subgroup analysis by formulation is limited. Whether higher-bioavailability formulations consistently outperform standard at equivalent serum curcumin is mechanistically plausible but not rigorously head-to-head tested at scale.

Optimal dose-response curve. Trial doses range across orders of magnitude (80 mg high-bioavailability formulations to 2,000+ mg standard + piperine) with comparable outcomes — because the actual plasma curcumin matters more than the label mg. The optimal dose-by-formulation curve isn't systematically characterized.

Cancer context dual role. Curcumin shows preclinical anti-cancer effects but can interact with chemotherapy in context-specific ways. Clinical implications for users with cancer history or active oncology treatment are not well-defined. Defer to oncologist.

Cognitive and Alzheimer's applications. Mechanistic case (BDNF, anti-amyloid) is strong; clinical trial results in Alzheimer's and MCI populations have been mixed. Whether higher doses, longer duration, or different formulations would produce reliable cognitive benefit is open.

Healthy-adult primary prevention. The strongest evidence is in symptomatic populations (osteoarthritis pain, ulcerative colitis, post-exercise inflammation). Whether curcumin produces meaningful benefit in asymptomatic healthy adults as a longevity / chronic-disease-prevention intervention is mechanistically reasonable but not directly RCT-supported with hard endpoints.

Multi-year safety at high doses. Trial data extends to 12 months in many populations. Multi-decade use at supplemental doses is reasonable based on safety profile and culinary history but not directly RCT-characterized.

Where to buy curcumin

Curcumin is widely available over-the-counter. Quality variation is unusually large for this supplement — primarily because the bioavailability differences between standard curcumin and patented formulations are 7–30×, making formulation choice the dominant practical quality marker. The screen below is what we use before clicking through.

Quality markers to look for

  • Patented high-bioavailability formulation — Meriva (phytosome), Theracurmin (nanoparticle), BCM-95 (curcumin + turmeric oils), or Longvida (lipid-coated). These have trial-validated absorption and clinical effect.
  • Standard curcumin + piperine (BioPerine) as cheaper alternative — 95% curcuminoids + 5–20 mg piperine. ~20× absorption vs curcumin alone.
  • Avoid plain turmeric powder or generic curcumin without piperine/bioavailability formulation — essentially placebo at typical supplemental doses.
  • Standardized to 95% curcuminoids — should be on every label for non-patented formulations.
  • Third-party tested — USP, NSF, or ConsumerLab certifications signal independent verification. Heavy-metal testing relevant (turmeric has documented lead-adulteration issues in some Indian sources).
  • cGMP-certified manufacturing facility — minimum bar for any supplement.
  • No proprietary blends that obscure the actual curcumin dose alongside fillers.
  • Fresh manufacture date — curcuminoids degrade with prolonged exposure to heat and light.
Shop Curcumin on Amazon →

Amazon affiliate link — Prof. Peptide earns a small commission on qualifying purchases at no extra cost to you. We use commissions to fund research and editorial work.

Curcumin FAQ

Standard curcumin vs Meriva vs BCM-95 vs Theracurmin — which form should I take?

Bioavailability is the central issue for curcumin — standard curcumin powder has near-zero oral absorption (single-digit nanomolar plasma levels at standard doses). The high-bioavailability formulations solve this in different ways: Meriva (curcumin-phosphatidylcholine complex) increases plasma curcumin ~29× vs standard; Theracurmin (nanoparticle dispersion) ~27× vs standard; BCM-95 (curcumin + turmeric essential oils) ~7×; standard curcumin + piperine (BioPerine) ~20× via inhibiting hepatic glucuronidation. Practical default: pick any of the patented high-bioavailability forms (Meriva, Theracurmin, Longvida, BCM-95) at trial-validated doses. Standard turmeric powder or generic curcumin extract is largely a placebo at typical supplemental doses.

How much curcumin do I need for joint pain?

Depends on form. With a high-bioavailability formulation: 200–500 mg/day delivers serum curcumin equivalent to gram-doses of standard curcumin. With standard curcumin + piperine: 1,000–2,000 mg curcumin + 5–20 mg piperine daily. The Paultre 2021 osteoarthritis meta-analysis pooled doses ranging from 80 mg (high-bioavail formulations) to 2,000 mg (standard + piperine) and found consistent pain reduction and functional improvement comparable to NSAIDs. Don't get hung up on raw mg — pick a clinically-validated formulation and follow its trial dose.

Is curcumin really as effective as ibuprofen for arthritis?

For mild-to-moderate knee osteoarthritis pain, several head-to-head trials show curcumin produces comparable pain reduction and functional improvement to ibuprofen, naproxen, or diclofenac — with significantly fewer GI side effects (ulcer risk, bleeding). Effect sizes for both NSAIDs and curcumin are modest in absolute terms — neither is a cure for arthritis. The practical edge for curcumin is the safety profile: long-term NSAID use carries real cardiovascular and GI risks; long-term curcumin doesn't. For acute severe pain, NSAIDs still win on speed. For chronic mild-moderate joint pain management, curcumin is a reasonable alternative or rotation partner.

Will curcumin help with exercise recovery and muscle soreness?

Modestly, with reasonable evidence. Multiple trials and a 2017 meta-analysis show curcumin supplementation around hard training events reduces post-exercise muscle damage markers (creatine kinase, lactate dehydrogenase), reduces perceived muscle soreness, and may modestly accelerate strength recovery. Effect sizes are smaller than for joint pain. Protocols typically use 150–500 mg of high-bioavailability curcumin daily for 7 days surrounding a hard training event, similar to the tart cherry protocol. Useful adjunct in training-block recovery, not a foundational performance supplement.

Can I stack curcumin with BPC-157 or TB-500?

Yes — and the stack is mechanistically natural for users targeting tissue recovery and inflammation. BPC-157 is a healing peptide that accelerates tissue repair through angiogenic and growth-factor signaling — particularly relevant for tendon, ligament, and gut injuries. TB-500 (thymosin beta-4 fragment) supports cell migration, wound healing, and tissue regeneration. Curcumin operates at a different layer: NF-κB inhibition and COX/LOX reduction blunt the systemic inflammatory response that's often the limiting factor in injury healing. The peptides drive the repair signaling; curcumin reduces the inflammatory background. Mechanistically complementary, no known negative interactions. KPV (anti-inflammatory tripeptide) is a third option in this cluster — particularly for users targeting gut inflammation alongside joint or tissue concerns.

Should I worry about curcumin and blood thinners?

Yes, this is the most clinically relevant interaction. Curcumin has documented mild antiplatelet effects — modestly additive with warfarin, aspirin, NSAIDs, clopidogrel, apixaban, and rivaroxaban. For most healthy users, the effect is subclinical. For users on chronic anticoagulation or scheduled for surgery, the interaction matters: stop curcumin 1–2 weeks before scheduled surgery, and coordinate with prescribing clinicians if you're on warfarin (INR monitoring during titration) or other anticoagulants. The newer DOACs (apixaban, rivaroxaban) have less rigorous monitoring; defer to your prescriber.

Can I get the same benefits from cooking with turmeric instead of supplements?

Partially — and the gap is huge for systemic effects. Culinary turmeric contains ~2–5% curcumin by weight, with the same near-zero oral bioavailability problem. Indian-style curries with turmeric also typically include black pepper (piperine) and fat (oil, ghee, coconut milk) — which dramatically improves the modest absorption. So daily turmeric-heavy cooking provides some bioactive curcumin, but the dose is far below supplemental ranges. For inflammation-modulating doses (200–500 mg high-bioavailability curcumin daily): supplementation is required. Cooking with turmeric is a fine adjunct and a culinary tradition; it's not a substitute for therapeutic dosing.

How long until I notice curcumin's effects?

Anti-inflammatory and joint-pain effects typically emerge over 4–8 weeks of consistent dosing. Don't evaluate at 1–2 weeks — the inflammatory pathways curcumin modulates respond on slower timescales than acute analgesics. Some users notice modest mood improvements or reduced GI inflammation earlier (2–4 weeks). If you've taken a high-bioavailability curcumin formulation at trial-validated dose for 8 weeks and noticed nothing, curcumin probably isn't your lever — don't keep escalating the dose hoping for an effect that didn't appear at the evidence-supported range.

References

  1. Paultre K, Cade W, Hernandez D, Reynolds J, Greif D, Best TM. Therapeutic effects of turmeric or curcumin extract on pain and function for individuals with knee osteoarthritis: a systematic review. BMJ Open Sport Exerc Med. 2021;7(1):e000935. https://pubmed.ncbi.nlm.nih.gov/33500785/
  2. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92. https://pubmed.ncbi.nlm.nih.gov/29065496/
  3. Fernández-Lázaro D, Mielgo-Ayuso J, Seco-Calvo J, et al. Effects of curcumin supplementation on inflammatory markers, muscle damage, and sports performance during acute physical exercise in sedentary individuals: a systematic review. Int J Environ Res Public Health. 2020;17(8):2891. https://pubmed.ncbi.nlm.nih.gov/32316576/
  4. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502-1506. https://pubmed.ncbi.nlm.nih.gov/17101300/
  5. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807-818. https://pubmed.ncbi.nlm.nih.gov/17999464/
  6. Sanmukhani J, Satodia V, Trivedi J, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014;28(4):579-585. https://pubmed.ncbi.nlm.nih.gov/23832433/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

BMJ Open Sport & Exercise Medicine · 2021Open Access
Therapeutic Effects of Turmeric or Curcumin Extract on Pain and Function for Individuals with Knee Osteoarthritis →

Paultre K, Cade W, Hernandez D, Reynolds J, Greif D, Best TM

A systematic review and meta-analysis of 16 RCTs (n=1,810) of turmeric/curcumin extract in knee osteoarthritis. Curcumin produced significant pain reduction (VAS score) and functional improvement (WOMAC) versus placebo, with effect sizes comparable to NSAIDs in head-to-head comparisons. GI adverse events were significantly lower than NSAID arms. The Paultre 2021 meta-analysis is the most-cited modern evidence summary for curcumin in osteoarthritis — and the foundational reference for the 'NSAID-comparable with better safety' framing.

Foods · 2017Open Access
Curcumin: A Review of Its Effects on Human Health →

Hewlings SJ, Kalman DS

A comprehensive review of curcumin biology, bioavailability solutions, and clinical evidence across inflammatory, metabolic, cardiovascular, neurological, and oncology applications. Covers the NF-κB inhibition mechanism, COX/LOX pathway effects, BDNF upregulation, and the bioavailability problem that drove the development of patented formulations (Meriva, Theracurmin, BCM-95, Longvida). Useful as a single-source reference for the curcumin evidence landscape.

International Journal of Environmental Research and Public Health · 2020Open Access
Effects of Curcumin Supplementation on Exercise-Induced Muscle Damage: A Systematic Review →

Fernández-Lázaro D, Mielgo-Ayuso J, Seco-Calvo J, Córdova Martínez A, Caballero-García A, Fernandez-Lazaro CI

A systematic review of 11 RCTs (n=240) of curcumin supplementation around strenuous exercise. Curcumin significantly reduced post-exercise creatine kinase, IL-6, TNF-α, and muscle soreness versus placebo. Effect sizes were modest but consistent. Most protocols used 150–500 mg of high-bioavailability curcumin for 5–10 days surrounding the exercise event. Supports curcumin as an exercise-recovery adjunct in training-block contexts.

Clinical Gastroenterology and Hepatology · 2006Paywalled
Curcumin: A Two-Edged Sword? Targeting Inflammation in Inflammatory Bowel Disease →

Hanai H, Iida T, Takeuchi K, et al.

A randomized double-blind placebo-controlled trial of 1 g curcumin twice daily for 6 months in 89 patients with ulcerative colitis in remission. Curcumin significantly reduced relapse rates versus placebo (4.65% vs 20.51%) and improved clinical activity and endoscopic indices. The Hanai 2006 trial established curcumin as an evidence-based maintenance therapy for ulcerative colitis remission and demonstrated the gut-anti-inflammatory use case beyond joint pain.

Molecular Pharmaceutics · 2007Paywalled
Bioavailability of Curcumin: Problems and Promises →

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB

The foundational review of curcumin bioavailability — the central practical problem for translating mechanistic and preclinical evidence into clinical effect. Documents that standard curcumin produces single-digit nanomolar plasma levels (well below in-vitro effective concentrations), and reviews the bioavailability-enhancing strategies (piperine co-administration, phospholipid complexes, nanoparticles, liposomal delivery) that subsequent patented formulations were built on. The Anand 2007 paper is the reference document for understanding why formulation choice matters more than dose for curcumin.

Anti-InflammatoryNF-κB InhibitorOsteoarthritisBioavailabilityMerivaHealing Cluster

Related Supplements

Fish OilCollagen PeptidesQuercetinZinc CarnosineTart Cherry

We may earn commissions from peptide vendor affiliate links.

Have a question about Curcumin? Send us an email →